Lipid-modifying therapy and attainment of cholesterol goals in Hungary: The Return on Expenditure Achieved for Lipid Therapy (REALITY) study

Clinical Drug Investigation

Volumn 27, Issue 9, 2007, Pages 647-660

  Paragh, György ^a   Márk, Lászlo ^b   Zámolyi, Károly ^c   Pados, Gyula ^d   Ofner, Péter ^e  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b Pandy Kalman County Hospital   (Hungary)

^c BAJCSY ZSILINSZKY HOSPITAL   (Hungary)

^d Szent Imre Hospital   (Hungary)

^e National Institute of Cardiology Budapest   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; ANALYTICAL PARAMETERS; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY RISK; DRUG POTENCY; FEMALE; GENERAL PRACTITIONER; HIGH RISK POPULATION; HUMAN; HUNGARY; ISCHEMIC HEART DISEASE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; OBSERVATIONAL STUDY; POPULATION RISK; PRIORITY JOURNAL; RISK ASSESSMENT; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL; CLOFIBRIC ACID; COST-BENEFIT ANALYSIS; DRUG COSTS; DRUG THERAPY, COMBINATION; FEMALE; GUIDELINE ADHERENCE; HUMANS; HUNGARY; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PRACTICE GUIDELINES; QUESTIONNAIRES; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 34548090213     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200727090-00006     Document Type: Article

References (72)

1. World Health Organization. Atlas of heart disease and stroke: types of cardiovascular disease 2005 [online]. Available from URL: http//www.who.int [Accessed 2006 Apr 10]
2. Petersen S, Peto V, Rayner M, et al. European cardiovascular disease statistics: 2005 edition [online]. Available from URL: http://www.ehnheart.org/ cms/site/showdoc.asp?.id=5883 [Accessed 2006 May 23]
3. European Heart Network. CVD statistics: statistical data about cardiovascular disease in Europe [online]. Available from URL: http://www.ehnheart.org/content/sectionintro.asp?.level0=1457 [Accessed 2006 May 23]
4. Józan P. Fordulat a halandósában és az életkilátásokban, epidemiológiai korszakváltás Magyarországon? New trends in mortality and life expectancy: epidemiologic transition in Hungary? Orv Hetil 2003; 144: 451-60
5. Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistic-2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommit tee. Circulation 2006; 113: e85-151
6. Ministry of Health, Hungary (Budapest). Johan Béla National Programme for the Decade of Health [online]. Available from URL: http://www.eum.hu/eum/eum_angol.head page?.pid=DA_22059. 2003 [Accessed 2006 Jun 12]
7. EUROASPIRE (European Action on Secondary Prevention through Intervention to Reduce Events) Study Group. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. Eur Heart J 1997; 18: 1569-82
8. EUROASPIRE II Study Group. Lifestyle and risk factor man agement and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001; 22: 554-72
9. EUROASPIRE I and II Group. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet 2001; 357: 995-1001
10. Ose L, Skjeldestad FE, Bakken IJ, et al. Lipid management and cholesterol goal attainment in Norway. Am J Cardiovasc Drugs 2006; 6: 121-8
11. Van Ganse E, Laforest L, Alemao E, et al. Lipid-modifying therapy and attainment of cholesterol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study. Curr Med Res Opin 2005; 21: 1389-99
12. Van Ganse E, Souchet T, Laforest L, et al. Ineffectiveness of lipid-lowering therapy in primary care. Br J Clin Pharmacol 2005; 59: 456-63
13. Goettsch WG, Yin DD, Alemao E, et al. Statins are less effective in common daily practice among patients with hypercholesterolemia: the REALITY-PHARMO study. Curr Med Res Opin 2004; 20: 1025-33
14. Garcia Ruíz FJ, Ibanez AM, Perez-Jimenez F, et al. Current lipid management and low cholesterol goal attainment in common daily practice in Spain: the REALITY study. Pharmacoeconomics 2004; 22 Suppl. 3: 1-12
15. Pearson TA, Laurora I, Chu H, et al. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000; 160: 459-67
16. Sueta CA, Chowdhury M, Boccuzzi SJ, et al. Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am J Cardiol 1999; 83: 1303-7
17. Marcelino JJ, Feingold KR. Inadequate treatment with HMG-CoA reductase inhibitors by health care providers. Am J Med 1996; 100: 605-10
18. Schectman G, Hiatt J. Drug therapy for hypercholesterolemia in patients with cardiovascular disease: factors limiting achievement of lipid goals. Am J Med 1996; 100: 197-204
19. Krobot KJ, Yin DD, Alemao E, et al. Real-world effectiveness of lipid-lowering therapy in male and female outpatients with coronary heart disease: relation to pre-treatment low-density lipoprotein-cholesterol, pre-treatment coronary heart disease risk, and other factors. Eur J Cardiovasc Prev Rehabil 2005; 12: 37-45
20. Krobot KJ, Yin DD, Alemao E, et al. LDL-cholesterol levels attained on lipid-lowering therapy: the relationship to pretreatment CHD risk and pretreatment LDL-cholesterol (REALITY-Study Germany) [abstract]. Atherosclerosis 2004; 5: 129
21. Karády I. A kardiovaszkularis terapias konszenzus konferencia lipidcsokkento ajanlasai az ateroszklerozis prevenciojara es kezelesere (The lipid lowering recommendations of the Hungarian National Consensus Conference). Metabolizmus 2004; 2: 8-12
22. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502
23. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000; 101: 207-13
24. Bautista MC, Engler MM. The Mediterranean diet: is it cardioprotective? Prog Cardiovasc Nurs 2005; 20: 70-6
25. Trichopoulou A, Bamia C, Trichopoulos D. Mediterranean diet and survival among patients with coronary heart disease in Greece. Arch Intern Med 2005; 165: 929-35
26. Trichopoulou A, Orfanos P, Norat T, et al. Modified Mediterranean diet and survival: EPIC-elderly prospective cohort study. BMJ 2005; 330: 991-7
27. Kern J, Strnad M, Coric T, et al. Cardiovascular risk factors in Croatia: struggling to provide the evidence for developing policy recommendations. BMJ 2005; 331: 208-10
28. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-504
29. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227-39
30. Hasdai D, Behar S, Wallentin L, et al. A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin; the Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS). Eur Heart J 2002; 23: 1190-201
31. Östör E, Jánosi A, Ádám Z, et al. A koszorúér-betegség msodlagos prevenciója. Helyzetkép az ezredfordulón az EUROASPIRE I-II vizsgálat magyar adatainak tükrében (Secondary prevention of coronary disease: at the turn of the millennium in light of the Hungarian data of the EUROASPIRE I-II studies). Orv Hetil 2003; 144: 2933-404
32. Davidson M, Ma P, Stein EA, et al. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am J Cardiol 2002; 89: 268-75
33. Muls E, De Backer G, Brohet C, et al. The efficacy of atorvasta tin in treating patients with hypercholesterolaemia to target LDL-cholesterol goals: the LIPI-GOAL trial. Acta Cardiol 2001; 56: 109-14
34. Garmendia F, Brown AS, Reiber I, et al. Attaining United States and European guideline LDL-cholesterol levels with simvastatin in patients with coronary heart disease (the GOALLS study). Curr Med Res Opin 2000; 16: 208-19
35. Hunninghake D, Bakker-Arkema RG, Wigand JP, et al. Treating to meet NCEP-recommended LDL cholesterol concentrations with atorvastatin, fluvastatin, lovastatin, or simvastatin in patients with risk factors for coronary heart disease. J Fam Pract 1998; 47: 349-56
36. McBride P, Schrott HG, Plane MB, et al. Primary care practice adherence to National Cholesterol Education Program guidelines for patients with coronary heart disease. Arch Intern Med 1998; 158: 1238-44
37. Yarzebski J, Bujor CF, Goldberg RJ, et al. A community-wide survey of physician practices and attitudes toward cholesterol management in patients with recent acute myocardial infarction. Arch Intern Med 2002; 162: 797-804
38. Fornengo P, Bruno G, De Salvia A, et al. Low adherence of general practitioners to National Cholesterol Education Program guidelines for the management of hyperlipidaemia. Diabetes Nutr Metab 2000; 13: 263-8
39. Foley KA, Simpson Jr RJ, Crouse III JR, et al. Effectiveness of statin titration on low-density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events. Am J Cardiol 2003; 92: 79-81
40. Adult Treatment Panel III. Third Report of the National Choles terol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-421
41. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004; 291: 1071-80
42. Amarenco P, Bogousslavsky J, Callahan III A, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355: 549-59
43. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425-35
44. De Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004; 292: 1307-16
45. Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study. A randomized controlled trial. JAMA 2005; 294: 2437-45
46. Mok HY, von Bergmann K, Grundy SM. Effects of continuous and intermittent feeding on biliary lipid outputs in man: application for measurements of intestinal absorption of cholesterol and bile acids. J Lipid Res 1979; 20: 389-98
47. Garcia-Calvo M, Lisnock J, Bull HG, et al. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci U S A 2005; 102: 8132-7
48. Gagné C, Bays HE, Weiss SR, et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002; 90: 1084-91
49. Stein E, Stender S, Mata P, et al. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: effi cacy and safety of ezetimibe co-administered with atorvastatin. Am Heart J 2004; 148: 447-55
50. Pearson TA, Denke MA, McBride PE, et al. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin Proc 2005; 80: 587-95
51. Ballantyne CM, Abate N, Yuan Z, et al. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. Am Heart J 2005; 149: 464-73
52. Ballantyne CM, Houri J, Notarbartolo A, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003; 107: 2409-15
53. Cruz-Fernandez JM, Bedarida GV, Adgey J, et al. Efficacy and safety of ezetimibe co-administered with ongoing atorvastatin therapy in achieving low-density lipoprotein goal in patients with hypercholesterolemia and coronary heart disease. Int J Clin Pract 2005; 59: 619-27
54. Brohet C, Banai S, Alings AM, et al. LDL-C goal attainment with the addition of ezetimibe to ongoing simvastatin treatment in coronary heart disease patients with hypercholesterolemia. Curr Med Res Opin 2005; 21: 571-8
55. Farnier M, Volpe M, Massaad R, et al. Effect of co-administering ezetimibe with on-going simvastatin treatment on LDL-C goal attainment in hypercholesterolemic patients with coronary heart disease. Int J Cardiol 2005; 102: 327-32
56. Ballantyne CM, Weiss R, Moccetti T, et al. Efficacy and safety of rosuvastatin 40mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). Am J Cardiol 2007; 99: 673-80
57. Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002; 40: 2125i-34i
58. Blagden MD, Chipperfield R. Efficacy and safety of ezetimibe co-administered with atorvastatin in untreated patients with primary hypercholesterolaemia and coronary heart disease. Curr Med Res Opin 2007; 23: 767-75
59. Goldberg RB, Guyton JR, Mazzone T, et al. Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study. Mayo Clin Proc 2006; 81: 1579-88
60. Ballantyne CM, Blazing MA, King TR, et al. Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am J Cardiol 2004; 93: 1487-94
61. Ballantyne CM, Lipka LJ, Sager PT, et al. Long-term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolemia. Int J Clin Pract 2004; 58: 653-8
62. Barrios V, Amabile N, Paganelli F, et al. Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease. Int J Clin Pract 2005; 59: 1377-86
63. Catapano AL, Davidson MH, Ballantyne CM, et al. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemia patients. Curr Med Res Opin 2006; 22: 2041-53
64. Goldberg AC, Sapre A, Capece R, et al. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2004; 79: 620-9
65. Armstrong EP, Zachry III WM, Malone DC. Cost-effectiveness analysis of simvastatin and lovastatin/extended-release niacin to achieve LDL and HDL goal using NHANES data. J Manag Care Pharm 2004; 10: 251-8
66. Kashyap M, McGovern ME, Berra K, et al. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol 2002; 89: 672-8
67. Pasternak RC, Smith Jr SC, Bairey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation 2002; 106: 1024-8
68. Athyros VG, Papageorgou AA, Merouris BR, et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus usual care in secondary heart disease preven tion: the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin 2007; 18: 220-8
69. Erhardt LR. Barriers to effective implementation of guideline recommendations. Am J Med 2005; 118 (12A): 36S-41S
70. Grant RW, O'Leary KM, Weilbrug JB, et al. Impact of concurrent medication use on statin adherence and refill persistence. Arch Intern Med 2004; 164: 2343-8
71. Benner JS, Tierce JC, Ballantyne CM, et al. Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy. Pharmacoeconomics 2004; 22 Suppl. 3: 13-23
72. Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood presgram sure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA 2006; 296: 2563-71